<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810238</url>
  </required_header>
  <id_info>
    <org_study_id>C3BS-C-07-01</org_study_id>
    <secondary_id>EudraCT 2007-007699-40</secondary_id>
    <nct_id>NCT00810238</nct_id>
  </id_info>
  <brief_title>C-Cure Clinical Trial</brief_title>
  <official_title>C-Cure - Safety, Feasibility and Efficacy of Guided Bone Marrow-derived Mesenchymal Cardiopoietic Cells for the Treatment of Heart Failure Secondary to Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celyad (formerly named Cardio3 BioSciences)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celyad (formerly named Cardio3 BioSciences)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate the feasibility, safety and efficacy of
      left ventricular endocardial injection of guided bone marrow-derived cardiopoietic cells
      (C-Cure) in the setting of chronic heart failure secondary to ischemic cardiomyopathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular ejection fraction</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-min walking distance</measure>
    <time_frame>6 months, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Each follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>Each follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Heart Failure Class II or III</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal standard of care + C-Cure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Optimal standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C-Cure</intervention_name>
    <description>Intraventricular injection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 18 and &lt; 75 years old;

          -  Subject has Heart Failure, New York Heart Association (NYHA) class II or class III
             with LVEF &gt; 15% and ≤ 40% as assessed by transthoracic echocardiography;

          -  Subject has ischemic heart disease;

          -  Subject has an identifiable (by transthoracic echocardiography) area of transmural
             scar within the left ventricle;

          -  Subject is on optimal and stable medical therapy for more than 2 months;

          -  Subject is willing and able to undergo an ICD implantation, prior to receiving C-Cure™
             or already has an ICD implanted;

          -  Subject agrees to comply with all follow-up evaluations;

          -  Subject has been informed of the nature of the clinical trial and agrees to its
             provision and has provided written informed consent.

        Exclusion Criteria:

          -  Subject has been treated with cell-based therapy;

          -  Subject has myocardial revascularization by PCI or CABG within 2 months prior to
             enrolment;

          -  Subject has had an MI within 2 months prior to enrolment;

          -  Subject is planned for PCI, CABG or any cardiac surgery;

          -  Subject has received a biventricular pacemaker within 6 month prior to enrolment;

          -  Subject has moderate to severe aortic valve heart disease, aortic or mitral prosthetic
             valve;

          -  Subject has a significant mitral valve insufficiency (Effective Regurgitant Orifice
             (ERO) &gt; 0.2 cm²) with possibility of mitral valve surgery;

          -  Subject has left ventricular thrombus;

          -  Subject has LV aneurysma or is a candidate for surgical aneurysmectomy;

          -  Subject LV ventricular wall thickness is &lt; 5 mm in the target territory;

          -  Subject has proven high grade atrioventricular block or sustained ventricular
             tachyarrhythmias;

          -  Subject has an hemodynamically significant congenital heart disorder;

          -  Subject has clinical evidence for infection or active malignancy;

          -  Subject has known stable chronic kidney dysfunction with serum creatinine &gt; 2.5 mg/dL
             at two occasions during the screening period;

          -  Subject has experienced severe adverse reaction/allergies to contrast agents;

          -  Subject has atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries
             of a degree, that could impede or preclude the safe retrograde passage of the delivery
             catheter, in the judgment of the investigator;

          -  Subject is on chronic immunosuppressive transplant therapy;

          -  Subject had an autologous or allogenic bone marrow or peripheral stem cell transplant
             or prior solid organ transplantation;

          -  Subject has a multisystem disease;

          -  Subject has been tested positive for Human Immunodeficiency Virus (HIV 1 or HIV 2),
             Hepatitis B Virus (HBV), Hepatitis C (HCV) and/or syphilis;

          -  Women of child bearing potential;

          -  Subject has life expectancy &lt; 1 year from non heart failure related causes;

          -  Subject suffers from morbid obesity (Body Mass Index (BMI) &gt; 40);

          -  Subject has a recent history of alcohol or drug abuse;

          -  Subject has any other surgical or medical condition that, in the judgment of the
             investigator might warrant exclusion or be contraindicated for safety reasons;

          -  Subject is currently participating in another trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Bartunek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VZW Cardiovascular Research Center Aalst</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André Terzic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic, Rochester, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CardioVascular Center</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université Catholique de Louvain, Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <last_update_submitted>September 3, 2012</last_update_submitted>
  <last_update_submitted_qc>September 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

